Replies to post #107919 on Biotech Values

[DewDiligence]

how would MNTA know whether TEVA infringed their patents in characterizing lovenox?

Well, MNTA essentially drafted the FDA requirements for approvability set forth in #msg-52582225 to coincide with MNTA’s patent estate on Lovenox characterization. So it would be a good bet that any approved product would be infringing MNTA’s patents.

To reiterate, I don’t think this angle will ever actually come into play.